Free Trial

Xeris Biopharma (XERS) Stock Price, News & Analysis

-0.06 (-2.99%)
(As of 05/23/2024 ET)
Today's Range
50-Day Range
52-Week Range
910,762 shs
Average Volume
1.23 million shs
Market Capitalization
$289.11 million
P/E Ratio
Dividend Yield
Price Target

Xeris Biopharma MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
137.2% Upside
$4.63 Price Target
Short Interest
6.50% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
Insider Trading
Acquiring Shares
$9,720 Bought Last Quarter
Proj. Earnings Growth
From ($0.41) to ($0.20) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.45 out of 5 stars

Medical Sector

271st out of 915 stocks

Pharmaceutical Preparations Industry

114th out of 399 stocks

XERS stock logo

About Xeris Biopharma Stock (NASDAQ:XERS)

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

XERS Stock Price History

XERS Stock News Headlines

Q1 2024 Xeris Biopharma Holdings Inc Earnings Call
XERS Xeris Biopharma Holdings, Inc.
Q4 2023 Xeris Biopharma Holdings Inc Earnings Call
See More Headlines
Receive XERS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xeris Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
Pretax Margin
Return on Equity


Sales & Book Value

Annual Sales
$163.91 million
Book Value
($0.06) per share


Free Float
Market Cap
$289.11 million

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Paul R. EdickMr. Paul R. Edick (Age 68)
    Chairman & CEO
    Comp: $1.12M
  • Mr. John P. Shannon (Age 62)
    President & COO
    Comp: $827.72k
  • Ms. Beth P. Hecht J.D. (Age 60)
    Chief Legal Officer & Corporate Secretary
    Comp: $638.31k
  • Mr. Steven M. Pieper (Age 47)
    Chief Financial Officer
  • Ms. Allison Wey
    Senior Vice President of Investor Relations & Corporate Communications
  • Dr. Kenneth E. Johnson Pharm. D. (Age 61)
    Pharm.D., Senior VP of Global Development & Medical Affairs
  • Mr. Kevin McCulloch
    Chief Commercial Officer

XERS Stock Analysis - Frequently Asked Questions

Should I buy or sell Xeris Biopharma stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Xeris Biopharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" XERS shares.
View XERS analyst ratings
or view top-rated stocks.

What is Xeris Biopharma's stock price target for 2024?

4 Wall Street research analysts have issued 1-year price objectives for Xeris Biopharma's stock. Their XERS share price targets range from $3.00 to $6.00. On average, they anticipate the company's stock price to reach $4.63 in the next year. This suggests a possible upside of 137.2% from the stock's current price.
View analysts price targets for XERS
or view top-rated stocks among Wall Street analysts.

How have XERS shares performed in 2024?

Xeris Biopharma's stock was trading at $2.35 at the beginning of the year. Since then, XERS shares have decreased by 17.0% and is now trading at $1.95.
View the best growth stocks for 2024 here

When is Xeris Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our XERS earnings forecast

How were Xeris Biopharma's earnings last quarter?

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) released its earnings results on Thursday, May, 9th. The company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by $0.02. The business had revenue of $40.64 million for the quarter, compared to analyst estimates of $41.56 million. Xeris Biopharma had a negative net margin of 37.58% and a negative trailing twelve-month return on equity of 16,662.63%.

What ETFs hold Xeris Biopharma's stock?

ETFs with the largest weight of Xeris Biopharma (NASDAQ:XERS) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).

What guidance has Xeris Biopharma issued on next quarter's earnings?

Xeris Biopharma issued an update on its FY 2024 earnings guidance on Thursday, May, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $175.0 million-$200.0 million, compared to the consensus revenue estimate of $184.4 million.

What other stocks do shareholders of Xeris Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xeris Biopharma investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Miragen Therapeutics (MGEN), Novan (NOVN), Dynavax Technologies (DVAX), Zosano Pharma (ZSAN), Cogent Biosciences (UMRX) and Organigram (OGI).

When did Xeris Biopharma IPO?

Xeris Biopharma (XERS) raised $75 million in an IPO on Thursday, June 21st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Mizuho Securities was co-manager.

Who are Xeris Biopharma's major shareholders?

Xeris Biopharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (5.13%), Rosalind Advisors Inc. (2.01%), Invenomic Capital Management LP (0.41%), NEA Management Company LLC (0.28%), Alpine Global Management LLC (0.20%) and Diversified Trust Co (0.13%). Insiders that own company stock include Jeffrey W Sherman, John P Schmid, John Patrick Shannon Jr, Paul R Edick and Steven Prestrelski.
View institutional ownership trends

How do I buy shares of Xeris Biopharma?

Shares of XERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:XERS) was last updated on 5/24/2024 by Staff

From Our Partners